BRIC Cancer Therapeutics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
No. of Pages: 150 | Report Code: BMIRE00031442 | Category: Life Sciences
No. of Pages: 150 | Report Code: BMIRE00031442 | Category: Life Sciences
The cancer therapeutics market size is expected to reach US$ 80,766.61 million by 2031 from US$ 31,523.87 million in 2024. The market is estimated to record a CAGR of 13.07 % from 2025 to 2031.
The cancer therapeutics market in BRIC is experiencing significant growth driven by growing burden of breast and lung cancer and surging investments in oncology research. For instance, according to GLOBOCAN Statistics 2020, breast cancer caused 10.6% (90,408) of all fatalities and 13.5% (178,361) of all cancer cases in India, with a cumulative risk of 2.81. Furthermore, increasing product launches in breast cancer treatment, served by genomic approaches, targeted therapies, immunotherapies, etc., have also revolutionized the market landscape in India. These advancements have improved patient outcomes, along with creating opportunities for pharmaceutical companies to continue developing more innovative therapies.
Key segments that contributed to the derivation of the cancer therapeutics Market analysis are type and application.
The BRIC cancer therapeutics market is segmented into Russian Federation, Brazil, South Africa, India, and China. For instance, According to GLOBOCAN 2020, there were 592,212 cancer cases across the Brazil, comprising 300,144 males and 292,098 women, and breast cancer was among the most common types. According to the Brazilian National Cancer Institute (INCA), ~66,200 new cases of breast cancer in women are diagnosed in Brazil annually. In addition, the incidence of colorectal cancer is higher among older adults; ~55,102 new colorectal cancer cases were found in Brazil in 2020, as per GLOBOCAN 2020 data.
The Brazilian government has invested in healthcare infrastructure, enabling better access to oncology services. Initiatives such as the Brazilian National Cancer Institute (INCA) have played a crucial role in enhancing cancer care and supporting research. These combined factors, along with a growing emphasis on early detection and personalized medicine, propel the expansion of the cancer therapeutics market in Brazil.
Based on region, the BRIC cancer therapeutics Market is further segmented into the Russian Federation, Brazil, South Africa, India, and China. The China held the largest share in 2024.
As one of the most populous countries in the world, China is facing a growing cancer burden, and the incidence of cancer continues to rise. According to the World Health Organization (WHO), ~4.5 million new cancer cases and 3 million deaths due to cancer were reported in China in 2020. The WHO estimates indicate that approximately seven people are diagnosed with cancer and four die due to cancer in the country every minute. The most common types of cancer diagnosed are lung cancer, stomach cancer, breast cancer, thyroid cancer, and leukemia. According to a recent study named "Chronic Illness and Ageing in China," published in 2020, China's population is aging. From 2010 to 2040, it is estimated that the proportion of people aged 60 years and above in the country will rise from 12.4% (168 million) to 28% (402 million). With increasing life expectancy, the proportion of elderly people is also growing, and older adults are more susceptible to cancer.
The development of new and more effective therapies has significantly improved patient outcomes and survival rates, leading to a growing demand for these treatments. For instance, in July 2023, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Similarly, in January 2022, BeiGene, headquartered in China, won approval for Tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer from China National Medical Products Administration (NMPA).
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 31,523.87 Million |
| Market Size by 2031 | US$ 80,766.61 Million |
| Global CAGR (2025 - 2031) | 13.07 % |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Therapy Type
|
| Regions and Countries Covered | BRIC
|
| Market leaders and key company profiles |
Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These players adopt strategies such as expansion, product innovation, and mergers and acquisitions to stay competitive in the market and offer innovative products to their consumers.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:
The BRIC Cancer Therapeutics Market is valued at US$ 31,523.87 Million in 2024, it is projected to reach US$ 80,766.61 Million by 2031.
As per our report BRIC Cancer Therapeutics Market, the market size is valued at US$ 31,523.87 Million in 2024, projecting it to reach US$ 80,766.61 Million by 2031. This translates to a CAGR of approximately 13.07 % during the forecast period.
The BRIC Cancer Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the BRIC Cancer Therapeutics Market report:
The BRIC Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The BRIC Cancer Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the BRIC Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For BRIC Cancer Therapeutics Market
